Leerink Partnrs Has Strong Estimate for Medpace Q3 Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Investment analysts at Leerink Partnrs upped their Q3 2025 earnings per share estimates for Medpace in a research report issued on Tuesday, July 22nd. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings of $3.64 per share for the quarter, up from their previous estimate of $2.94. The consensus estimate for Medpace's current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace's Q4 2025 earnings at $3.71 EPS, FY2025 earnings at $14.11 EPS, FY2026 earnings at $15.78 EPS, FY2027 earnings at $18.22 EPS and FY2028 earnings at $20.93 EPS.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%. The business's quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.75 earnings per share.

Several other research analysts also recently issued reports on the company. Mizuho upped their price objective on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a research note on Friday. William Blair reaffirmed a "market perform" rating on shares of Medpace in a research note on Wednesday. Barclays upped their price objective on Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research note on Wednesday. Robert W. Baird upped their price objective on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research note on Wednesday. Finally, Truist Financial upped their price objective on Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $411.10.

Medpace Trading Down 1.8%

NASDAQ MEDP traded down $8.19 during trading on Friday, hitting $447.49. 763,602 shares of the company's stock were exchanged, compared to its average volume of 683,834. The company has a market cap of $12.57 billion, a PE ratio of 33.27, a P/E/G ratio of 2.91 and a beta of 1.47. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $501.30. The stock's 50 day moving average price is $319.66 and its two-hundred day moving average price is $321.05.

Hedge Funds Weigh In On Medpace

A number of institutional investors and hedge funds have recently modified their holdings of MEDP. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Brooklyn Investment Group raised its position in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after buying an additional 71 shares during the last quarter. Whittier Trust Co. raised its position in Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after buying an additional 35 shares during the last quarter. Colonial Trust Co SC raised its position in Medpace by 150.0% in the 4th quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after buying an additional 105 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Medpace in the 1st quarter valued at $60,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.